<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00440739</url>
  </required_header>
  <id_info>
    <org_study_id>SiEc 161/2548</org_study_id>
    <nct_id>NCT00440739</nct_id>
  </id_info>
  <brief_title>Etoricoxib With Flavoxate for Reducing Morphine Requirement After Transurethral Prostatectomy (TURP)</brief_title>
  <official_title>Etoricoxib With Flavoxate for Reducing Morphine Requirement After Transurethral Prostatectomy: A Factorial Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether etoricoxib, flavoxate, both are effective
      in the treatment postoperative pain after TURP.

      The research hypothesis:

      There is a difference in postoperative morphine consumption in the first 24 hours after
      transurethral prostatectomy between patients who received etoricoxib or flavoxate or both and
      placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postoperative pain is still a significant problem for surgical patients. Conventional use of
      narcotics for postoperative pain relief is not without serious side effects such as
      respiratory depression and sedation.There are other alternatives for postoperative analgesia
      as NSAIDs especially COX2-inhibitors. For some specific operation such as TURP which Foley's
      catheter needed to be retained for a few days,urinary anti spasmodics may help the patients
      to be more comfortable.

      Comparison(s): There is a difference in postoperative morphine consumption in the first 24
      hours after transurethral prostatectomy between patients who received etoricoxib or flavoxate
      or both and placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The patients' total amount of morphine requirement in the first 24 hour.</measure>
    <time_frame>24 hour</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1=placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2= etoricoxib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3=falvoxate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>etoricoxib and flavoxate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoricoxib</intervention_name>
    <description>etoricoxib 120 mg</description>
    <arm_group_label>2</arm_group_label>
    <other_name>arcoxia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>flavoxate</intervention_name>
    <description>flavoxate 200 mg 3 times</description>
    <arm_group_label>3</arm_group_label>
    <other_name>urispas</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoricoxib, flavoxate</intervention_name>
    <description>etoricoxib 120 mg once and flavoxate 200 mg 3 times</description>
    <arm_group_label>4</arm_group_label>
    <other_name>arcoxia</other_name>
    <other_name>urispas</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo once and placebo 3 times</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male patient ASA physical status I-III.

          2. Scheduled for an elective TURP.

          3. Body weight &gt; or = 50 kg

          4. Can operate a patient-controlled analgesia (PCA) device.

        Exclusion Criteria:

          1. History of asthma, acute rhinitis, nasal polyps, angioneurotic edema or urticaria
             following the administration of aspirin or other NSAIDs.

          2. Known hypersensitivity to morphine.

          3. History of hepatic dysfunction.

          4. Creatinine clearance &lt; 30ml/min.

          5. History of bleeding tendency.

          6. History of gastrointestinal bleeding or active peptic ulcer.

          7. Known case of inflammatory bowel disease.

          8. Patient with severe heart failure.

          9. History of coronary artery disease or cerebrovascular disease.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sirilak Suksompong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine Siriraj Hospital, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>February 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2006</study_first_submitted>
  <study_first_submitted_qc>February 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2007</study_first_posted>
  <last_update_submitted>February 4, 2009</last_update_submitted>
  <last_update_submitted_qc>February 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2009</last_update_posted>
  <responsible_party>
    <name_title>Ethic committee Mahidol University</name_title>
    <organization>Mahidol University</organization>
  </responsible_party>
  <keyword>postoperative pain, etoticoxib, etoricoxib</keyword>
  <keyword>Pain relief after transurethral resection of prostate.</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Etoricoxib</mesh_term>
    <mesh_term>Flavoxate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

